Increasing evidence in the literature reveals that KRAS mutation in tumors provides the intrinsic attributes of tumors, as well as contributes to the development of the tumor microenvironment (TME), which is significantly affected by the TME’s immune cells and ultimately contributes to immune escape and tumor progression [10,11]. This evidence concerns the gene KRAS and neoplasm.